MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.820
+0.020
+0.53%
After Hours: 3.820 0 0.00% 16:00 09/25 EDT
OPEN
3.790
PREV CLOSE
3.800
HIGH
3.940
LOW
3.790
VOLUME
6.33K
TURNOVER
--
52 WEEK HIGH
5.13
52 WEEK LOW
1.490
MARKET CAP
51.11M
P/E (TTM)
-22.2741
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
MACK, MTP, CODX and IGC among midday movers
Gainers: Midatech Pharma (MTP) +59%.Mesoblast (MESO) +51%.Sky Solar (SKYS) +45%.Merrimack Pharmaceuticals (MACK) +28%.Taiwan Liposome (TLC) +27%.Party City Holdco (PRTY) +21%.Ebang International (EBON) +20%.TFF Pharmaceuticals (TFFP) +16%.Agile Therapeutics (AGRX) +15%.LSB Industries (LXU) +14%.Losers: Hexindai (HX) -50%.Biofrontera
Seekingalpha · 08/14 16:46
Merrimack Pharmaceuticals reports Q2 results
Merrimack Pharmaceuticals (NASDAQ:MACK): Q2 GAAP EPS of -$0.09. Cash and cash equivalents and investments of $15.7M. Press Release
seekingalpha · 08/07 17:29
Merrimack Pharmaceuticals Yesterday Reported Q1 EPS $0.020 Up From $(0.780) YoY
Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly earnings of $0.020 per share. This is a 102.56 percent increase over losses of $(0.780) per share from the same period last year.
Benzinga · 05/08 14:48
Merrimack Reports First Quarter 2020 Financial Results
Business Wire · 05/07 23:10
Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
Seeking Alpha - Article · 04/14 20:20
Merrimack Pharma Reports Receipt Of $2.25M Related To Closing Of Asset Sale For Preclinical Nanoliposome Programs To Celator Pharma
Benzinga · 04/02 12:44
Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update
Business Wire · 04/02 12:30
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27)
Benzinga · 02/28 12:28
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MACK. Analyze the recent business situations of Merrimack Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MACK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 7.41M
% Owned: 55.42%
Shares Outstanding: 13.38M
TypeInstitutionsShares
Increased
5
55.97K
New
8
-55.72K
Decreased
10
297.28K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Treasurer/Director
Gary Crocker
Independent Director
Eric Andersen
Independent Director
Noah Levy
Controller
John Green
Independent Director
Ulrik Nielsen
Independent Director
Russell Ray
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.5007
12/13/2019
07/25/2019
Dividend USD 0
09/06/2019
07/25/2019
Special Dividend USD 1.5
09/06/2019
04/04/2017
Dividend USD 0
05/30/2017
04/04/2017
Special Dividend USD 1.055209
05/30/2017
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MACK
Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.